Repeated Low-Dose Mucosal Simian Immunodeficiency Virus SIVmac239 Challenge Results in the Same Viral and Immunological Kinetics as High-Dose Challenge: a Model for the Evaluation of Vaccine Efficacy in Nonhuman Primates
Open Access
- 15 March 2004
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (6), 3170-3177
- https://doi.org/10.1128/jvi.78.6.3140-3144.2004
Abstract
Simian immunodeficiency virus (SIV) challenge of rhesus macaques provides a relevant model for the assessment of human immunodeficiency virus (HIV) vaccine strategies. To ensure that all macaques become infected, the vaccinees and controls are exposed to large doses of pathogenic SIV. These nonphysiological high-dose challenges may adversely affect vaccine evaluation by overwhelming potentially efficacious vaccine responses. To determine whether a more physiologically relevant low-dose challenge can initiate infection and cause disease in Indian rhesus macaques, we used a repeated low-dose challenge strategy designed to reduce the viral inoculum to more physiologically relevant doses. In an attempt to more closely mimic challenge with HIV, we administered repeated mucosal challenges with 30, 300, and 3,000 50% tissue culture infective doses (TCID 50 ) of pathogenic SIVmac239 to six animals in three groups. Infection was assessed by sensitive quantitative reverse transcription-PCR and was achieved following a mean of 8, 5.5, and 1 challenge(s) in the 30, 300, and 3,000 TCID 50 groups, respectively. Mortality, humoral immune responses, and peak plasma viral kinetics were similar in five of six animals, regardless of challenge dose. Interestingly, macaques challenged with lower doses of SIVmac239 developed broad T-cell immune responses as assessed by ELISPOT assay. This low-dose repeated challenge may be a valuable tool in the evaluation of potential vaccine regimes and offers a more physiologically relevant regimen for pathogenic SIVmac239 challenge experiments.Keywords
This publication has 29 references indexed in Scilit:
- Major Histocompatibility Complex Class I Alleles Associated with Slow Simian Immunodeficiency Virus Disease Progression Bind Epitopes Recognized by Dominant Acute-Phase Cytotoxic-T-Lymphocyte ResponsesJournal of Virology, 2003
- Expression of the Major Histocompatibility Complex Class I Molecule Mamu-A*01 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 ReplicationJournal of Virology, 2003
- Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 InfectionJournal of Virology, 2002
- Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunityNature, 2002
- How important is the ‘quality’ of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection?Immunology Letters, 2001
- An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus RecombinantsCell, 2001
- Protection against Simian Immunodeficiency Virus Vaginal Challenge by Using Sabin Poliovirus VectorsJournal of Virology, 2001
- The dynamics of the cellular immune response to HIV infection: implications for vaccinationPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2000
- Maternal humoral factors associated with perinatal human immunodeficiency virus type-1 transmission in a cohort from Kigali, Rwanda, 1988–1994Journal of Infection, 1999
- Maternal Virus Load and Perinatal Human Immunodeficiency Virus Type 1 Subtype E Transmission, ThailandThe Journal of Infectious Diseases, 1999